Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

被引：417

作者：

Kipps, Emma ^{[1
]}

Tan, David S. P. ^{[2
]}

Kaye, Stan B. ^{[3
]}

机构：

[1] Royal Marsden Hosp, Inst Canc Res, Sutton SM2 5PT, Surrey, England

[2] Princess Margaret Hosp, Drug Dev Program, Toronto, ON M5G 2M9, Canada

[3] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

来源：

NATURE REVIEWS CANCER | 2013年 / 13卷 / 04期

基金：

英国惠康基金;

关键词：

ENDOTHELIAL GROWTH-FACTOR; PERITONEAL MESOTHELIAL CELLS; VASCULAR-PERMEABILITY FACTOR; PHASE-III TRIAL; MALIGNANT ASCITES; EPITHELIAL OVARIAN; LYSOPHOSPHATIDIC ACID; CARCINOMA CELLS; INTRAPERITONEAL BEVACIZUMAB; PERITONEOVENOUS SHUNTS;

D O I：

10.1038/nrc3432

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.

引用

页码：273 / 282

页数：10

共 160 条

[1]

Abrahams VM, 2003, CANCER RES, V63, P5573

[2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3]

Akriviadis EA, 1997, AM J GASTROENTEROL, V92, P567

[4] Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer [J].

Alberti, C. ;

Pinciroli, P. ;

Valeri, B. ;

Ferri, R. ;

Ditto, A. ;

Umezawa, K. ;

Sensi, M. ;

Canevari, S. ;

Tomassetti, A. .

ONCOGENE, 2012, 31 (37) :4139-4149

[5] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[6] Ovarian surface epithelium: Biology, endocrinology, and pathology [J].

Auersperg, N ;

Wong, AST ;

Choi, KC ;

Kang, SK ;

Leung, PCK .

ENDOCRINE REVIEWS, 2001, 22 (02) :255-288

[7] Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].

Ayantunde, A. A. ;

Parsons, S. L. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949

[8] Epithelial-mesenchymal transition in ovarian cancer progression:: A crucial role for the endothelin axis [J].

Bagnato, Anna ;

Rosano, Laura .

CELLS TISSUES ORGANS, 2007, 185 (1-3) :85-94

[9] Cancer and the chemokine network [J].

Balkwill, F .

NATURE REVIEWS CANCER, 2004, 4 (07) :540-550

[10] Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer:: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy [J].

Bamias, Aristotelis ;

Koutsoukou, Vasiliki ;

Terpos, Evangelos ;

Tsiatas, Marinos L. ;

Liakos, Christina ;

Tsitsilonis, Ourania ;

Rodolakis, Alexandros ;

Voulgaris, Zannis ;

Vlahos, G. ;

Papageorgiou, Theocharis ;

Papatheodoridis, G. ;

Archimandritis, A. ;

Antsaklis, A. ;

Dilnopoulos, M. A. .

GYNECOLOGIC ONCOLOGY, 2008, 108 (02) :421-427

← 1 2 3 4 5 6 7 8 9 10 →